HC Wainwright Reiterates Buy Rating for Transcat (NASDAQ:TRNS)

HC Wainwright reissued their buy rating on shares of Transcat (NASDAQ:TRNS) in a research report report published on Tuesday, Benzinga reports. They currently have a $124.00 price target on the scientific and technical instruments company’s stock. HC Wainwright also issued estimates for Transcat’s Q4 2024 earnings at $0.53 EPS, FY2024 earnings at $1.35 EPS and FY2025 earnings at $2.31 EPS.

Separately, TheStreet raised shares of Transcat from a c+ rating to a b rating in a report on Wednesday, January 31st.

Transcat Trading Up 2.7 %

NASDAQ TRNS opened at $108.04 on Tuesday. The company has a market capitalization of $953.89 million, a PE ratio of 83.11 and a beta of 0.59. The company has a fifty day moving average of $108.50 and a 200 day moving average of $102.00. Transcat has a 1 year low of $74.89 and a 1 year high of $115.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.37 and a quick ratio of 2.81.

Transcat (NASDAQ:TRNS) last posted its earnings results on Monday, January 29th. The scientific and technical instruments company reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.35 by $0.03. The company had revenue of $65.17 million during the quarter, compared to the consensus estimate of $63.36 million. Transcat had a net margin of 4.16% and a return on equity of 9.32%. Research analysts forecast that Transcat will post 1.33 earnings per share for the current year.

Insider Buying and Selling at Transcat

In other Transcat news, Director Charles P. Hadeed sold 700 shares of Transcat stock in a transaction on Monday, February 12th. The shares were sold at an average price of $113.00, for a total value of $79,100.00. Following the completion of the transaction, the director now owns 22,678 shares of the company’s stock, valued at $2,562,614. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Lee D. Rudow sold 2,373 shares of the business’s stock in a transaction dated Saturday, March 30th. The shares were sold at an average price of $111.43, for a total transaction of $264,423.39. Following the completion of the sale, the chief executive officer now owns 103,688 shares of the company’s stock, valued at $11,553,953.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Charles P. Hadeed sold 700 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $113.00, for a total transaction of $79,100.00. Following the sale, the director now directly owns 22,678 shares of the company’s stock, valued at approximately $2,562,614. The disclosure for this sale can be found here. Over the last quarter, insiders sold 8,073 shares of company stock valued at $900,023. Corporate insiders own 4.20% of the company’s stock.

Institutional Trading of Transcat

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Transcat by 13.3% during the third quarter. Vanguard Group Inc. now owns 425,378 shares of the scientific and technical instruments company’s stock worth $41,674,000 after purchasing an additional 49,828 shares in the last quarter. Monashee Investment Management LLC purchased a new stake in shares of Transcat during the third quarter worth about $588,000. Quadrature Capital Ltd purchased a new stake in shares of Transcat during the third quarter worth about $2,847,000. Rice Hall James & Associates LLC increased its stake in shares of Transcat by 59.2% during the third quarter. Rice Hall James & Associates LLC now owns 28,781 shares of the scientific and technical instruments company’s stock worth $2,820,000 after purchasing an additional 10,697 shares in the last quarter. Finally, Conestoga Capital Advisors LLC increased its stake in shares of Transcat by 0.6% during the fourth quarter. Conestoga Capital Advisors LLC now owns 762,861 shares of the scientific and technical instruments company’s stock worth $83,404,000 after purchasing an additional 4,805 shares in the last quarter. Hedge funds and other institutional investors own 98.34% of the company’s stock.

About Transcat

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.